The present invention provides a medicament containing a novel bispecific antigen-binding molecule for T cell activation and redirection to a specific target cell. A pharmaceutical comprising a T cell-activating bispecific antigen-binding molecule capable of specifically binding to CD3 and CEA, wherein the T cell-activating bispecific antigen-binding molecule has a specific sequence. Diseases include bladder cancer, brain cancer, head and neck cancer, pancreatic cancer, lung cancer, breast cancer, ovarian cancer, uterine cancer, cervical cancer, endometrial cancer, esophagus Cancer, colon cancer, colon cancer, rectal cancer, stomach cancer, prostate cancer, blood cancer, skin cancer, squamous cell cancer, bone cancer, and kidney cancer A medicine selected from the group consisting of: [Selection diagram] None【課題】Ｔ細胞活性化及び特定の標的細胞に対する再方向付けのための、新規の二重特異性抗原結合分子を含む医薬の提供。【解決手段】ＣＤ３及びＣＥＡに特異的に結合することができるＴ細胞活性化二重特異性抗原結合分子を含む医薬であって、Ｔ細胞活性化二重特異性抗原結合分子は特定の配列を有するポリペプチドを含み、疾病は、膀胱がん、脳がん、頭頸部がん、膵臓がん、肺がん、乳がん、卵巣がん、子宮がん、子宮頸がん、子宮内膜がん、食道がん、大腸がん（ｃｏｌｏｎ ｃａｎｃｅｒ）、大腸がん（ｃｏｌｏｒｅｃｔａｌ ｃａｎｃｅｒ）、直腸がん、胃がん、前立腺がん、血液がん、皮膚がん、扁平上皮がん、骨がん、及び腎臓がんから選択されるがんである、医薬。【選択図】なし
